The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster as a therapeutic suicide gene of breast cancer cells

Journal of Gene Medicine

Volumn 13, Issue 6, 2011, Pages 305-311

  Ma, Shuai ^a   Zhao, Lei ^a   Zhu, Zhi ^a   Liu, Qun ^a   Xu, Huimian ^a   Johansson, Magnus ^b   Karlsson, Anna ^b   Zheng, Xinyu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bystander effect; Dm dNK; Gene therapy; Molecular chemotherapy; Nucleoside analogs; Nucleoside kinase

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DROSOPHILA MELANOGASTER DEOXYRIBONUCLEOSIDE KINASE; RETROVIRUS VECTOR; RIBONUCLEOSIDE DERIVATIVE; THYMINE ARABINOSIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL LINE; CELL NUCLEUS; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SUICIDE GENE; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DROSOPHILA MELANOGASTER; FEMALE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RETROVIRIDAE; SUBSTRATE SPECIFICITY; TRANSDUCTION, GENETIC;

DROSOPHILA MELANOGASTER;

EID: 79959726916     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1573     Document Type: Article

References (19)

1. Wiechmann L, Kuerer HM. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 2008; 112: 2130-2142.
2. Rustogi A, Budrukkar A, Dinshaw K, et al. Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther 2005; 1: 21-30.
3. Bonini C, Bondanza A, Perna SK, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007; 15: 1248-1252.
4. Freeman SM, Abboud CN, Whartenby KA, et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
5. Zheng X, Johansson M, Karlsson A. Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem 2000; 275: 39125-39129.
6. Zheng X, Johansson M, Karlsson A. Bystander effects of cancer cell lines transduced with the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster and synergistic enhancement by hydroxyurea. Mol Pharmacol 2001; 60: 262-266.
7. Berk AJ, Clayton DA. A genetically distinct thymidine kinase in mammalian mitochondria. Exclusive labeling of mitochondrial deoxyribonucleic acid. J Biol Chem 1973; 248: 2722-2729.
8. Yu KD, Di GH, Wu J, et al. Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol 2007; 14: 2502-2509.
9. Monnier A. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol 2007; 18(Suppl 8): viii36-viii44.
10. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine 2007; 2: 567-583.
11. Degreve B, Johansson M, De Clercq E, et al. Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK. J Virol 1998; 72: 9535-9543.
12. Knecht W, Sandrini P.B., Johansson K, et al. A few amino acid substitutions can convert deoxyribonucleoside kinase specificity from pyrimidines to purines. EMBO Journal 2002; 21: 1873-1880.
13. Solaroli N, Johansson M, Balzarini J, et al. Enhanced toxicity of purine nucleoside analogs in cells expressing Drosophila melanogaster nucleoside kinase mutants. Gene Therapy 2007; 14: 86-92.
14. Solaroli N, Bjerke M, Amiri MH, et al. Active site mutants of Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. Eur J Biochem 2003; 270: 2870-2884.
15. Floeth FW, Shand N, Bojar H, et al. Local inflammation and devascularization-in vivo mechanisms of the 'bystander effect' in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther 2001; 8: 843-851.
16. Hasenburg A, Fischer DC, Tong XW, et al. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Int J Gynecol Cancer 2002; 12: 66-73.
17. Link CJ, Seregina T, Traynor A, et al. Cellular suicide therapy of malignant disease. Stem Cells 2000; 18: 220-226.
18. Wierdl M, Potter PM. Update on gene therapy approaches for cancer. Curr Hematol Rep 2005; 4: 294-299.
19. Yun HJ, Cho YH, Moon Y, et al. Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp Mol Med 2008; 40: 345-353.